key: cord-1041516-90x7o14i
authors: Cakir, Aysel; Bostan, Ecem; Kaymaz, Esin
title: Erythema annulare centrifugum following SARS‐CoV‐2 infection in a pediatric patient
date: 2022-04-11
journal: Int J Dermatol
DOI: 10.1111/ijd.16194
sha: 85eab420447fd4a86284c956d7ec5292f8330747
doc_id: 1041516
cord_uid: 90x7o14i

nan

the disease such as erythema multiforme, urticaria, vesicular exanthem, and pediatric inflammatory multisystem syndrome have been reported in the pediatric population. 1 A rare skin disease, erythema annulare centrifugum (EAC), has also been observed to develop following COVID-19 infection. 2 Herein, we would like to report a unique case of EAC associated with SARS-CoV-2 infection in a pediatric patient.

A 10-year-old boy was seen in the outpatient dermatology clinic for a rash of 14-months duration. It started as an erythematous plaque on the anterior chest which gradually expanded Although the most common symptom is itching, EAC is often asymptomatic. 5 Our case was diagnosed with EAC with clinical and histopathological findings. The short time interval (4 weeks) between the start of the lesion and COVID-19 diagnosis, supports the relationship between EAC and SARS-CoV-2 infection.

It has been suggested that tumor necrosis factor-alpha pathway plays an important role in the etiopathogenesis of EAC. 3 

CoV-2 infection may cause immune system dysregulation with the release of pro-inflammatory cytokines. Therefore, SARS-CoV-2 may contribute to the development of EAC. To date, there have been only two cases of EAC which developed following SARS-CoV-2. 2,6 The first case is a 35-year-old female patient reported from Italy, and the second case is a 37-yearold female patient from Spain. 2, 6 In conclusion, we report, to our knowledge, the first case of EAC associated with SARS-CoV-2 infection in a pediatric patient, which showed complete resolution with topical corticosteroid treatment.

Informed written consent was taken from the parent of the patients. 

Skin manifestations of COVID-19 in children: part 2

Erythema annulare centrifugum with anosmia and ageusia in a SARS-CoV-2 exposed patient successfully treated with doxycycline

Paraneoplastic erythema annulare centrifugum eruption (PEACE)

A novel therapeutic approach to erythema annulare centrifugum

Erythema annulare centrifugum induced by COVID-19 vaccination

Erythema annulare centrifugum triggered by SARS-CoV-2 infection

Funding source: None. doi: 10.1111/ijd.16194